New Risk • Jun 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪29.5m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₪29.5m market cap, or US$9.91m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Revenue is less than US$5m (US$3.2m revenue). Reported Earnings • Mar 31
Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024) Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Mar 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (US$1.2m revenue). Market cap is less than US$100m (₪39.5m market cap, or US$12.8m). New Risk • Dec 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪31.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$10m (₪31.7m market cap, or US$9.88m). Minor Risk Revenue is less than US$5m (US$1.2m revenue). New Risk • Aug 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪32.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (₪32.8m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (US$1.3m revenue). Tillkännagivande • May 16
NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025 NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025. Location: company offices, Israel New Risk • Apr 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪37.1m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (₪37.1m market cap, or US$9.90m). Minor Risk Revenue is less than US$5m (US$1.3m revenue). Reported Earnings • Mar 28
Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023) Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. New Risk • Mar 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪39.7m market cap, or US$11.0m). New Risk • Dec 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪35.1m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (₪35.1m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). New Risk • Dec 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪49.4m market cap, or US$13.6m). New Risk • Aug 24
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪44.8m market cap, or US$12.2m). Tillkännagivande • Aug 15
NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024 NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024 New Risk • Aug 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪48.6m market cap, or US$12.7m). Tillkännagivande • Mar 27
NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024 NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024, at 14:00 Israel Standard Time. Tillkännagivande • Mar 20
NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024 NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024 New Risk • Mar 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪42.6m market cap, or US$11.7m). New Risk • Jan 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪37.7m market cap, or US$10.1m). New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₪29.6m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue). Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent External Director Oren Mohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Tillkännagivande • Aug 17
NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022 NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022 Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Leah Karmel Goren was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 03
Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020) Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020). Tillkännagivande • Feb 03
NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato Varieties NRGene and Philoseed announced a major milestone in the development of high resistant tomato varieties to overcome the tomato brown rugose fruit virus – ToBRFV. This advance encompasses the discovery of a unique region in the tomato genome, essential to the tomatoes’ resistance to the virus. The companies are in the process of patent protection of this previously unreported genomic region. The highly contagious tomato virus has been spreading rapidly in Europe, Asia, Africa, and in parts of Mexico and the US, threatening the tomato industry worldwide. This discovery of a unique tomato genomic region is another step forward towards complete resistance solution. It will facilitate the development of DNA markers and seeds of ToBRFV high resistance (HR) tomato varieties and is expected to be completed by the end of 2022. NRGene is currently offering immediate access to the discovered genomic region and DNA markers, and has already signed several commercial contracts, commercializing ToBRFV HR trait with Israeli, European and US companies. Tillkännagivande • Mar 04
Nrgene Announces Successful Completion and Results of the Canola/Rapeseed Pan-Genome NRGene announced the successful completion and results of the canola/rapeseed pan-genome. The International Canola Pan-genome Consortium was established in 2019 to advance the rapeseed agricultural industry by capturing this crop's broad genetic diversity. The global consortium was led jointly by Dr. Isobel Parkin from the Government of Canada’s Agriculture & Agri-food Canada (AAFC), Dr. Andrew Sharpe from the Global Institute for Food Security (GIFS) at the University of Saskatchewan, Canada, and NRGene. The consortium included key players in the canola industry, among them Bayer, Corteva Agriscience, Nutrien Ag Solutions and Nuseed. Each contributed their own canola lines to the research and received the full pangenome comparison results. Rapeseed is a major oil seed crop considered to be a high-quality vegetable oil and commonly used in food production and various industrial applications, including biofuel. According to the United Nation’s Food and Agriculture Organization, rapeseed is farmed on approximately 35 million acres globally and produced 85 million tons in 2019. Canola is the brand name for Canadian rapeseed varieties. Extensive breeding is done globally, focusing on developing higher yielding and more nutritional rapeseed varieties that can naturally resist plant diseases. The use of DNA markers already enhanced canola breeding over the past three decades. Yet, due to canola’s genome complexity, diversity, and instability, the need for a whole genome understanding became a bottleneck in canola breeding. Building a pan-genome database to unravel the broad genomic diversity in canola is the key to expanding the crop’s productivity. Tillkännagivande • Feb 23
NRGene and Kayagene Announces Exclusive Agreement for Commercialization of the Autoflower Trait of Cannabis NRGene and Kayagene signed an agreement that grants NRGene a world-wide, exclusive license to commercialize the Cannabis autoflower trait and DNA markers linked to it. Utilizing NRGene’s proprietary genomic tools and Kayagene’s proprietary germplasm and breeding knowledge the two companies recently identified the markers associated with the trait. The DNA markers will enable breeders to develop elite autoflower varieties quicker and more efficiently than before. NRGene will offer to license the autoflower trait and linked DNA markers to breeders and growers around the world, while Kayagene will be responsible for delivery of the seeds and pollen harboring the trait. Tillkännagivande • Feb 11
NRgene and Kayagene Announces the Completion of Milestone in Their Strategic Research Collaboration NRGene and Kayagene announced the completion of a milestone in their strategic research collaboration. This ongoing collaboration was initiated over 2 years ago, beginning with genomic assembly of several of Kayagene’s cannabis and hemp breeding lines, using NRGene’s DenovoMAGIC™ technology. Now, the companies have successfully mapped several key genes including the autoflowering gene, which is a highly desired trait and of great interest for the hemp and cannabis industries. NRGene estimates, that following the development of DNA markers for the autoflowering trait, it is now possible to integrate this trait into any hemp and cannabis variety within 12 to 18 months. Trait mapping and marker-assisted breeding are vital in a competitive market because it accelerates the time to market for unique and improved varieties harboring those key traits. The use of molecular markers enables rapid and accurate selections and reduces the presence of deleterious genes introduced by traditional breeding methods. 
